Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorMayo Clinic
About this trial
The purpose of this study is to evaluate the safety and tolerability of 1 mg osilodrostat therapy in patients with mild autonomous cortisol secretion (MACS), and to determine the impact on 24h urine steroid metabolome and circadian cortisol/cortisone concentrations
Eligibility criteria
Qualifiers
Provide written informed consent
Stated willingness to comply with all study procedures and availability for the duration of the study
Age ≥ 18 years
Diagnosed with MACS
Disqualifiers
Planned alternative therapy for MACS during the study period
Current use of oral exogenous glucocorticoid therapy
Current use of opioid therapy >20 MME/day
Planned use of oral exogenous glucocorticoid therapy
Trial design
Treatments tested in this trial
- Osilodrostat 1 MG
Treatment groups
15 Participants
are divided into 1 treatment groupLocations
1Mayo Clinic55905, RochesterMinnesota, United States
Sponsors and collaborators
Mayo Clinic
Lead sponsor
RECORDATI GROUP
Collaborator
Source ClinicalTrials.gov